Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 762.36

+3.4%

3:24 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (2167)	7/31/2017 1:18:01 PM
From: Miljenko Zuanic	of 3559

AD market is not RA/psoriasis or cancer! Not even close. I mentioned early that Dupi price reflect (opportunity) Allergic and overall asthma market, not AD. So, I expected difficulty in early lunch. But, from Rx number one would hope better refill numbers,...which they are not. Now, I would like to hear your explanation, If any? Point is that PBMs (Script and CVS, and others as well) did put restriction on Rx approval...and that is opposite what Sanofi and REGN are preaching. I would like to be wrong here, but would believe it only when I see correct numbers.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next